A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
An Open-Label Part is added:
This part will enroll in selected sites which are less affected by the COVID-19 pandemic.
150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized
into 3 groups according to the post-baseline biopsy.
The objective of the Open-Label Part is:
- To evaluate the safety and PK of twice daily administration (BID) of Aramchol 300mg in
subjects with NASH and liver fibrosis.
- To explore the kinetics of histological outcome measures and Non-Invasive Tests (NITs)
associated with NASH and fibrosis for the treatment duration of 24, 48 and 72 weeks.
All patients will be allocated to Aramchol.
Double Blind Part:
This part is double blind, placebo controlled randomized in subjects with NASH and fibrosis
stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes.
The primary objectives of this part of the study are to evaluate the effect of Aramchol as
compared to placebo on NASH resolution, fibrosis improvement and clinical outcomes related to
progression of liver disease.
Subjects will be randomized to receive Aramchol 300mg BID or matching placebo in a 2:1
randomization ratio.